Marker Therapeutics financials
$1.10−2.22%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $1.1M | $1.2M | $0.00 | $0.00 | $2.3M | $1.9M | $1.2M | $1.2M | $1.1M | $257.6K |
| Gross profit | $0.00 | $0.00 | $1.1M | $1.2M | $0.00 | $0.00 | $2.3M | $1.9M | $1.2M | $1.2M | $1.1M | $257.6K |
| Gross margin | — | — | 100.0% | 100.0% | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$2.6M | -$4.1M | -$1.9M | -$2.1M | -$5.1M | -$5.0M | -$3.9M | -$2.4M | -$2.3M | -$2.5M | -$2.9M | -$3.2M |
| Net income | -$1.8M | -$3.2M | -$1.7M | -$2.0M | -$4.0M | -$4.4M | -$3.8M | -$2.3M | -$2.2M | -$2.4M | -$2.8M | -$3.0M |
| Net margin | — | — | −154.4% | −162.1% | — | — | −170.4% | −119.8% | −187.5% | −192.3% | −265.3% | −1157.6% |
| Diluted EPS | $-0.09 | $-0.16 | $-0.09 | $-0.12 | $-0.29 | $-0.40 | $-0.42 | $-0.26 | $-0.25 | $-0.27 | $-0.32 | $-0.34 |
| EBITDA | -$2.6M | -$4.1M | -$1.9M | -$2.1M | -$5.1M | -$4.5M | -$3.9M | -$2.4M | -$2.3M | -$2.5M | -$2.9M | -$3.2M |
| Operating cash flow | -$3.7M | -$1.4M | -$1.9M | -$2.7M | -$1.9M | -$5.5M | -$4.7M | $1.2M | -$3.6M | -$3.8M | -$2.4M | -$1.1M |
| Free cash flow | -$3.7M | -$1.4M | -$1.9M | -$2.7M | -$1.9M | -$5.5M | -$4.7M | $1.2M | -$3.6M | -$3.8M | -$2.4M | -$1.1M |
| Diluted shares | 19.3M | 19.3M | 19.4M | 16.8M | 14.0M | 11.1M | 9.2M | 8.9M | 8.9M | 8.9M | 8.9M | 8.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $11.3M | $14.9M | $16.1M | $17.6M | $10.5M | $13.7M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $14.6M | $17.4M | $19.1M | $21.7M | $14.8M | $17.0M |
| Total liabilities | $2.4M | $3.6M | $2.3M | $3.3M | $4.3M | $2.5M |
| Shareholders' equity | $12.2M | $13.8M | $16.8M | $18.4M | $10.5M | $14.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology